- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01312506
Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls
Procurement of Central Nervous System and Extracranial Tumor Tissues, Cerebrospinal Fluid, and Serum/Plasma From Patients With Metastatic Melanoma to the CNS and Respective Controls for Gene Expression and Proteomic Profiling
This study has two ultimate goals:
- Understand how the original melanoma from the skin spreads to the CNS. In order to study this we need to collect (and compare) the original skin melanoma, the CNS melanoma, as well as any other melanoma that has not metastasized to the CNS.
- Develop a diagnostic blood test that will early identify subjects at high risk for developing CNS metastasis or patients who may already have CNS metastasis but the MRI or the CAT scan cannot yet detect it. Thus, the investigators plan to collect CSF from subjects like you who have melanoma CNS metastases in order to confirm the presence of this biomarker.
Přehled studie
Postavení
Podmínky
Typ studie
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
Regarding patients with distant metastatic melanoma and established melanoma CNS metastases who are scheduled for craniotomy:
Histologically confirmed, primary cutaneous melanoma, metastatic to the CNS (brain OR spinal cord OR carcinomatous meningitis) based on:
- Pathologic confirmation (i.e. prior craniotomy) OR
- Radiography (brain MRI or CT scan with intravenous contrast)
- Patients must have no contraindications for and be able to undergo lumbar puncture for CSF collection
- Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent, or will be acceptable if documented from a previous visit within the prior 30 days
- Subjects must have provided written, informed consent (ICF) prior to any study procedures
- Subjects must provide a FFPE tissue block containing a biopsy from the primary site
Regarding patients with distant metastatic melanoma and established melanoma CNS metastases who are not having a craniotomy and before they undergo external beam irradiation or stereotactic radiosurgery (patient's and/or neurosurgeon's preference):
Histologically confirmed melanoma (unknown primary, mucosal, ocular are allowed), metastatic to the CNS (brain OR spinal cord OR carcinomatous meningitis) based on
- Pathologic confirmation (i.e. prior craniotomy) and/or
- Radiography (brain MRI or CT scan with intravenous contrast)
- Patients must have no contraindications for and be able to undergo lumbar puncture for CSF collection
- Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent, or will be acceptable if documented from a previous visit within the prior 30 days
- Subjects must have provided written ICF prior to any study procedures
Regarding patients who have distant metastatic melanoma without radiographically detectable melanoma CNS metastases but are willing to undergo lumbar puncture:
- Histologically confirmed melanoma (unknown primary, mucosal, ocular are allowed),
- Patients must have no contraindications to lumbar puncture
- Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent, or will be acceptable, if documented from a previous visit within the prior 30 days
- Subjects must have provided written ICF prior to any study procedures
Regarding healthy volunteers
- Patients must have no contraindications to lumbar puncture (see Table 1)
- Patient must answer NO to all questions listed in Appendix B
- Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent or will be acceptable if documented from a previous visit within the prior 30 days
- Subjects must have provided written, ICF prior to any study procedures
Exclusion Criteria:
- For study subjects, patients with extradural lesions, i.e. those that originate from the bone (calvarium or vertebrae), will not be considered.
- Any significant psychiatric disease, medical intervention, or other conditions, which in the opinion of the Investigators, could impair proper discussion of the informed consent or compromise participation to the clinical trial.
- Active systemic treatment for metastatic melanoma within 2 days from the collection of specimens (brain tumor tissue, peripheral blood, CSF). Corticosteroids, other immunosuppressive anti-inflammatory and anti-epileptic medications are allowed.
- Patients who have undergone whole brain irradiation therapy within the last 30 days. Therefore neither CNS lesions nor CSF are considered suitable for collection.
- Patients with growing CNS lesions at an area that has previously undergone radiosurgery within 3 months prior to enrollment in this study. Therefore CNS tumors from previously irradiated areas using radiosurgery are not considered suitable for collection although CSF is allowed for collection.
- Brain abscess.
- Patients with new focal findings on neurological examination.
- Infected skin over the lumbar puncture needle entry site.
- Other conditions that at the opinion of the investigator are contraindicated.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Case-Control
- Časové perspektivy: Budoucí
Kohorty a intervence
Skupina / kohorta |
---|
Subjects undergoing a craniotomy
This group will include those subjects who have consented to have either a craniotomy or a laminectomy to resect an intramedullary tumor.
|
Metastases, no craniotomy
These subjects have metastases but have either chosen not to undergo removal of the cancer or their neurosurgeon does not recommend surgical approach or they have been diagnosed with metastatic melanoma but do not have CNS metastases.
|
Healthy Volunteers
Subjects who do not have known melanoma or metastases.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Stergios Moschos, MD, University of Pittsburgh
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 10-067
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Metastatický melanom
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.NáborMetastatický melanom | Konjunktivální melanom | Oční melanom | Neresekovatelný melanom | Uveální melanom | Kožní melanom | Slizniční melanom | Melanom duhovky | Akrální melanom | Nekutánní melanomSpojené státy
-
University of Southern CaliforniaNational Cancer Institute (NCI)DokončenoRecidivující melanom | Melanom fáze IV | Slizniční melanom | Melanom řasnatého tělíska a cévnatky, střední/velký | Melanom řasnatého tělíska a cévnatky, malá velikost | Melanom duhovky | Metastatický nitrooční melanom | Recidivující nitrooční melanom | Nitrooční melanom stadia IV | Melanom stadia IIIA | Melanom... a další podmínkySpojené státy
-
National Cancer Institute (NCI)DokončenoRecidivující melanom | Melanom stadia IIIA | Melanom stadia IIIB | Melanom stadia IIIC | Melanom stadia IIB | Melanom stadia IIC | Melanom stadia IA | Melanom stadia IB | Melanom stadia IIASpojené státy
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaDokončenoStádium IIIB kožní melanom | Stádium IIIC kožní melanom | Stupeň III kožní melanom | Melanom kůže stadia IIA | Melanom kůže stadia IIB | Kožní melanom stadia IIC | Stádium IIIA kožní melanom | Stádium IA kožní melanom | Stádium IB kožní melanom | Stádium 0 kožní melanom | Stádium I kožní melanom | Melanom kůže IISpojené státy
-
National Cancer Institute (NCI)DokončenoMelanom fáze IV | Melanom řasnatého tělíska a cévnatky, střední/velký | Melanom duhovky | Melanom stadia IIIA | Melanom stadia IIIB | Melanom stadia IIIC | Extraokulární extenzní melanom | Melanom stadia IIB | Melanom stadia IICSpojené státy
-
MelanomaPRO, RussiaNáborKlinické výsledky a biomarkery u pacientů s melanomem stadia 0-IV v reálné klinické praxi (ISABELLA)Melanom | Melanom (kůže) | Melanom stadium IV | Melanom stadium III | Melanom, stadium II | Melanom, Uveal | Melanom na místě | Melanom, očníRuská Federace
-
Mayo ClinicNational Cancer Institute (NCI)DokončenoRecidivující melanom | Melanom fáze IV | Melanom stadia IIIA | Melanom stadia IIIB | Melanom stadia IIIC | Melanom stadia IIB | Melanom stadia IIC | Melanom stadia IIASpojené státy
-
BiocadNáborMelanom | Melanom (kůže) | Melanom stadium IV | Melanom stadium III | Metastatický melanom | Neresekovatelný melanom | Pokročilý melanomIndie, Ruská Federace, Bělorusko
-
Emory UniversityGenentech, Inc.Aktivní, ne náborStupeň IV kožní melanom | Stádium IIIB kožní melanom | Stádium IIIC kožní melanom | Neresekovatelný melanom | Melanom fáze III | Stádium IIIA kožní melanom | Kožní melanom, stadium III | Kožní melanom, stadium IVSpojené státy
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)DokončenoStupeň IV kožní melanom | Recidivující melanom | Stádium IIIB kožní melanom | Stádium IIIC kožní melanom | Melanom kůže stadia IIA | Melanom kůže stadia IIB | Kožní melanom stadia IIC | Stádium IIIA kožní melanom | Stádium IA kožní melanom | Stádium IB kožní melanomSpojené státy